

SMI's 15<sup>th</sup> Annual Conference  
Advances and Progress in Drug Design  
15-16 February 2016  
Holiday Inn, Kensington Forum, London, UK

This event will focus on enabling biophysical tools and highlight key advancements in protein-based drug discovery, with new areas of discussion including: Small molecules in drug design - A look at novel inhibitors and favourable protein-fragment interactions.

Plus talks on strategic designs of compound libraries and data mining techniques will examine IMI Open PHACTS project as well as fragment deconstruction approaches and the result of halogen-mediated interactions.

Moreover, it will take a closer look at combined HTS and FBDD methods for lead generation and the application of biophysical methods such as: X-Ray Crystallography, NMR, biocore and ITC to aid the prioritization of target inhibitors.

Sponsored by: Chemical Computing Group, OpenEye Scientific Software, NanoTemper Technologies

To register please visit: [www.drug-design.co.uk](http://www.drug-design.co.uk)

Alternatively, contact Matthew Apps on: 44 (0) 20 7827 6093 or [mapps@smi-online.co.uk](mailto:mapps@smi-online.co.uk)

Plus two interactive post-conference workshops:

WORKSHOP A: A Fresh View on Molecular Recognition: The Dynamic Perspective (Barcelona University)

WORKSHOP B: Analysis and Application of Ligand Conformation in Drug Design (C4X Discovery)

KEY SPEAKERS:

- Gregg Seigal, Chief Executive Officer, ZoBio
- Tove Sjogren, Associate Director, AstraZeneca
- Herman van Vlijmen, Senior Director, Janssen
- Armin Ruf, Section Head, Biostructure, Roche
- Gianni Chessari, Director, Astex Pharmaceuticals
- Hans Matter, Senior Scientist, Sanofi-Aventis
- Jordi Munoz Muriedas, Investigator, GSK
- Manuel Francisco Molina-Martin, Research Scientist, Eli Lilly